The combination of empagliflozin and sitagliptin to treat type-2 diabetes might be more economical and patient compliance with an additive improvement in glycemic control due to complementary modes of action. To design, formulate and optimize an immediate tablet dosage form containing empagliflozin and sitagliptin utilizing statistically reliable study design followed by in-vitro and in-vivo testing. ology: To determine the effects of copovidone (X1) and croscarmellose sodium (X2) amounts on the dependent variables of disintegration time and percent drug release, the formulation was developed using Design Expert Software v.13's direct compression method-based central composite design optimization study. The formulations' assay, dissolution, friability, hardness, weight variation, disintegration, and anti-diabetic effects were evaluated in comparison to the standard drug. The analysis included the use of high performance liquid chromatography (HPLC) assay methods. Mice were employed to investigate the efficacy of an anti-diabetic drug after they were administered a high-fat diet and two injections of streptozotocin at a dosage of 30 mg/kg BW each. Formulation of F3 out of nine had all in-vitro parameters at the most satisfactory condition. It was found that assay of the best formulation is 100.99% and 100.19% for empagliflozin and sitagliptin respectively. The disintegration time of F3 was found at 5.32 min. Percentage release of empagliflozin in 30 min was found 89.05% while sitagliptin was with 93.76%. The results showed that administration of F3 significantly reduced FBG (68.61%, p < 0.0001), total cholesterol levels (70.29 ± 0.48; p < 0.0001), triglycerides (70.20 ± 0.40, p < 0.0001); HDL levels (52.50 ± 0.31; p < 0.0001), LDL levels (33.34 ± 0.28; p < 0.0001), compared to diabetic control, this effect was comparable to metformin treatment. The direct compression approach has been used to develop, and optimize a new combination tablet incorporating empagliflozin and sitagliptin with better dissolution rate and anti-diabetic action.
9 April 2024 in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
Collagen is an excellent biomaterial. Biological characteristics of collagen including biodegradability and weak antigenicity made it a primary resource in medical application. In biomedical field collagen is mainly used as sponges for wound/burn, supplement in rheumatoid arthritis, drug delivery system, controlling material for transdermal delivery and basic matrices for cell culture system due to its ability to stimulate formation of tissue and organ. Moreover, collagen is also applied in tissue engineering including bone defect, tissue regeneration, skin replacement and artificial blood vessels and valves. The article reviews biomedical application of collagen in wound healing, rheumatoid arthritis, drug delivery system, tissue engineering and lung function improvement in pulmonary fibrosis due to viral infection.
This study analyzed 89 packaged bakery products (65 biscuits, 16 cakes, and 8 breads) from Dhaka, Bangladesh, using GC–FID and FAAS. Biscuits and cakes contained high mean total fat (19.52 and 18.08 g/100 g) and saturated fat (saturated fatty acid [SFA]) levels, with 81% of all samples classified as “High SFA.” The polyunsaturated‐to‐SFA (PUFA:SFA) ratio was below 1.0 in all biscuit and cake samples, whereas bread showed more favorable ratios. Sodium content was highest in biscuits (mean 421.08 mg/100 g), followed by cakes (326.31 mg/100 g) and bread (277.00 mg/100 g). The results demonstrate that commonly consumed biscuits and cakes in Dhaka have nutrient profiles high in saturated fats and sodium, indicating a potential cardiovascular health risk, whereas bread represents a comparatively safer dietary option.